Participants sought for research studies and clinical trials

Please see below, the list of trials available in each research area

Haematology View

Currently recruiting Monash Haematology Clinical trials

Group	Disease \| Line of therapy / Setting \| Study title \| Phase \| Description	Principal Investigator
AML	AML (KMT2A/NPM1) \| Newly diagnosed, intensive chemo eligible \| Menin — 75276617ALE1001 \| Phase 3 \| Double‑blinded Bleximenib vs placebo with induction + consolidation	Dr Chyn Chua
AML	AML \| RR AML or MCL \| PEP07‑101 \| Phase 1b \| PEP07 Chk1 inhibitor monotherapy	Prof Jake Shortt
AML	AML \| CR1/CR2 or oligoblastic relapse \| Intercept — ALLG AMLM26 \| Platform (Phase 2/3 domains) \| MRD‑triggered multi‑arm precision platform	Dr Chyn Chua
AML	AML \| CR1 post induction \| CADENCE — ALLG AMLM22 \| Phase 2/3 \| Oral azacitidine vs oral azacitidine + Vididencil vaccine	Prof Jake Shortt
AML	AML \| ND AML on Ven‑Aza \| Adapt‑STOP — ALLG AMLM28 \| Phase 2 \| Randomised cessation of Ven‑Aza in MRD‑negative ND AML	Dr Chyn Chua
AML	AML/MDS/AML‑MDS \| ND & RR \| Apollo — AP30CP01 \| Phase 1 \| APL‑4098 ± azacitidine ± venetoclax	Dr Chyn Chua
AML	AML (NPM1/KMT2A) \| RR \| Menin — 75276617ALE1001 \| Phase 1/2 \| Bleximenib monotherapy	A/Prof Pasquale Fedele
MDS	MDS (IDH1+) \| Newly diagnosed \|PyramIDH — PyramIDH \| Phase 3 \| Ivosidenib vs azacitidine	Dr Chyn Chua
MDS/AML	AML/MDS \| ND/RR \| Apollo — AP30CP01 \| Phase 1 \| APL‑4098 ± azacitidine ± venetoclax	Dr Chyn Chua
MDS / MPN‑MDS	Transfusion‑dependent \| TD \| REDDS2 — REDDS2 \| Randomised feasibility \| Weekly vs usual transfusion schedule	Dr Allison Mo
CMML	CMML (TET2/RAS) \| Treatment‑naive \| PREACH‑M — PREACH‑M \| Phase 2 \| Mutation‑directed Aza + sodium ascorbate or Aza + lenzilumab	Dr Ashvind Prabahran
MPN	MF (JAK‑exposed) \| RR \| TP‑3654 — BBI‑TP3654‑102 \| Phase 1/2 \| TP‑3654 ± momelotinib (Arm 3 open)	Dr Paul Yeh
MPN	MF (suboptimal Ruxolitinib) \| Ruxolitinib inadequate response \| Navtemadlin — KRT‑232‑115 \| Phase 3 \| Navtemadlin + ruxolitinib vs placebo + ruxolitinib	Dr Paul Yeh
MPN	MF (JAK‑naive) \| ND \| Manifest‑3 — CDAK539A12303 \| Phase 3 \| Pelabresib + ruxolitinib vs placebo + ruxolitinib	Dr Paul Yeh
MPN	ET/PV/pre‑MF \| Treatment‑naive \| JBI‑802 — JBI‑802‑102 \| Phase 1/2 \| Dose‑finding JBI‑802 in thrombocytosis	Dr Paul Yeh
MPN	CML \| Previously treated \| CARDINAL — TERN‑701‑1012 \| Phase 1/2 \| Allosteric BCR::ABL1 inhibitor TERN‑701	Prof Jake Shortt
CLL/SLL	CLL \| Treatment‑naive \| BGB‑11417‑304 \| Phase 3 \| Sonrotoclax + zanubrutinib vs venetoclax + acalabrutinib	Prof Stephen Opat
CLL/SLL	CLL \| RR \| MOSUN — BO43243 \| Phase 1 \| Mosunetuzumab monotherapy or mosun + venetoclax	Prof Stephen Opat
CLL/SLL	CLL \| RR \| CELESTIAL‑RRCLL — BGB‑11417‑303 \| Phase 3 \| Sonrotoclax + anti‑CD20 vs venetoclax + rituximab	Prof Stephen Opat
CLL/SLL	CLL/SLL \| RR \| AETHER — ALLG CLL12 \| Phase 1/2 \| Venetoclax + epcoritamab (6 vs 12 cycles)	Prof Stephen Opat
CLL/SLL	CLL/SLL \| RR/TN \| BGB‑16673‑104 (Substudy 1b) \| Phase 1b/2 \| CDAC + sonrotoclax	Dr Ross Salvaris
CLL/SLL	CLL/SLL \| Post‑Ven/Obi \| MOONSHOT — ALLG CLL11 \| Phase 2 \| Epcoritamab monotherapy	Prof Stephen Opat
Indolent B-NHL	WM \| RR \| BGB‑16673‑104 (Substudy 1b) \| Phase 1b/2 \| CDAC + sonrotoclax	Dr Ross Salvaris
MCL	MCL \| RR \| PEP07‑101 \| Phase 1b \| Chk1 inhibitor monotherapy	Prof Jake Shortt
DLBCL	DLBCL \| RR \| NextGen — 95566692LYM1001 \| Phase 1 \| CD79b×CD20×CD3 trispecific antibody	Dr Ross Salvaris
DLBCL	DLBCL \| MRD‑positive post‑1L \| ALPHA‑3 — ALLO‑501A‑202 \| Phase 2 \| Cemacabtagene ansegedleucel CAR‑T	Dr Danielle Oh
B-cell NHL	DLBCL B‑cell lymphoma \| RR \| PALISADES‑1 — KT‑US‑499‑0150 \| Phase 1/2 \| KITE‑363 or KITE‑753 autologous anti‑CD19/CD20 CAR‑T therapies	Dr Danielle Oh
T‑cell NHL	Cytotoxic lymphoma / LGLL \| RR \| DR‑01 — DR‑01‑ONC‑001 \| Phase 1/2 \| DR‑01 monotherapy	Prof Jake Shortt
Myeloma	MM \| Newly diagnosed \| TRIlogy‑2 — 79635322MMY1002 \| Phase 1b \| JNJ‑79635322 + daratumumab ± IMiD	A/Prof Michael Low
Myeloma	MM \| RR (≥3 lines) \| TRIlogy‑4 — 79635322MMY3001 \| Phase 3 \| JNJ‑79635322 vs BCMA×CD3 bispecific	Dr Jeremy Er
Myeloma	MM \| RR (t(11;14)) \| BGB‑11417‑105 \| Phase 1b/2 \| Sonrotoclax + carfilzomib + dexamethasone	A/Prof Michael Low
Myeloma	MM \| RR (Len‑exposed) \| Quintessential — CA088‑1007 \| Phase 3 \| CAR‑T vs DPd/Kd	Dr Danielle Oh
Non‑Malignant	ITP / AIHA \| RR \| INCA00585 \| Phase 2a \| Tafasitamab monotherapy	Dr Ashwini Bennett
Non‑Malignant	Sickle Cell \| ND/RR \| Hibiscus‑2 \| Phase 3 \| Etavopivat vs placebo	Dr Zane Kaplan
Non‑Malignant	ITP \| RR \| TAK‑079‑3002 \| Phase 3 \| Mezagitamab vs placebo	Dr Zane Kaplan
Non‑Malignant	VTE \| – \| Butterfly \| Phase 2 \| LMWH via indwelling SC catheter	Dr Emma Leitinger
Non‑Malignant	Hypogammaglobulinemia \| – \| Rational‑PT \| Adaptive platform \| Adaptive IG replacement/cessation/dosing	Dr Ross Salvaris
Registry	Blood cancers \| All AML/ALL/MPN/MM \| National Blood Cancer Registry (NBCR) \| Registry \| National registry supporting AML platform trials and blood cancer outcomes	Dr Chyn Chua
Registry	Lymphoma / CLL \| All B‑cell malignancies \| LaRDR \| Registry \| Lymphoma and Related Diseases Registry	Prof Stephen Opat
Registry	Myeloma \| All MM \| Myeloma Registry \| Registry \| National myeloma outcomes registry
Registry	TTP \| TTP \| TTP Registry \| Registry \| National registry for thrombotic thrombocytopenic purpura

Title of study	Posted	Recruitment end date	Further info and contact
Improving dementia diagnosis in down syndrome	18 Mar 2025		Madeleine Healy Madeleine.healy@monashhealth.org
Methylenedioxymethamphetamine (MDMA) trial	21 Aug 2024	Jun 2025	Sarah-Jane Brighthope Sarah-Jane.Brighthope@monash.edu

Title of study	Posted	Recruitment end date	Further info and contact
Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (ASPRE-T)	16 May 2024	25 Dec 2025	A/Prof Daniel Rolnik 03 9594 5487 or 0452 105 585 daniel.rolnik@monash.edu
Biomarkers to improve outcomes of complications in pregnancy – BIOCiP	11 Jan 2023	28 Feb 2025	Dr Yizhen (Amy) Liu 03 9594 6666 Yizhenamy.liu@monashhealth.org
A randomised Trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study.	08 Dec 2022	31 Dec 2025	Prof Ben W. Mol 03 9594 5383 Ben.Mol@monash.edu

Clinical Sciences at Monash Health

Medicine, Nursing and Health Sciences

Participants sought for research studies and clinical trials

Please see below, the list of trials available in each research area

Haematology View

Currently recruiting Monash Haematology Clinical trials

Nutrition, Dietetics and Food View

Psychiatry View

Women's Health View